Rezolute Inc. (RZLT)

[Whalatane]

https://ir.rezolutebio.com/news-events/press-releases/detail/330/rezolute-reports-positive-topline-results-from-phase-2

“The results are monumental for the DME community,” said Quan Dong Nguyen, MD, MSc, FAAO, FARVO, FASRS, Professor of Ophthalmology at the Byers Eye Institute, and Professor of Medicine and Professor of Pediatrics at the Stanford University School of Medicine, and a member of Rezolute’s Scientific Advisory Board. “I am impressed by the significant reduction in CST in this study across all three dosages as retinal thickness is the key biomarker to determine whether a therapy may offer a potential benefit to patients.
These data are very encouraging and are supportive of the potential for a new first-line, non-invasive treatment for DME.”

Kiwi